| Today's Open | $63.50 |
|---|---|
| Previous Close | $63.13 |
| Daily Range | $63.14 - $63.65 |
| 52-Week Range | $38.63 - $64.48 |
| Market Cap | $178.4B |
| P/E Ratio | 0.00 |
| Dividend (Yield) | $0.00 (2.6%) |
| Volume | 300,739 |
| Average Daily Volume | 452,607 |
| Current FY EPS | $3.97 |
Sector
Healthcare
Industry
Pharmaceuticals
News & Commentary
Will ASCO Unlock Big Value in This Cancer Drug Class?
With the American Society of Clinical Oncology's annual meeting less than two weeks away, see what drug class could see big gains in the wake of new abstract data.Cancer Meeting Highlights the Good and Bad of the Immune System
The immune system can kill tumors, but it can also go haywire.Tackling Cancer: Endometrial Cancer's Biggest Current and Upcoming Players
Cancer research is big business, and it pays to know where research dollars are headed.Why Allergan's Pain Is Regeneron's Gain
Regeneron shareholders can see clearly now after Allergan's vision-loss drug hits a snag.Is Thermo Fisher Getting a Good Deal With Life Technologies?
Thermo Fisher buys Life Technologies for $13.6 billion, but is it a good deal?Roche, Isis Pharmaceuticals to Develop Huntington's Disease Treatments
Companies agree to an alliance to find therapies for the brain disorderIsis: Big Pharma's Little Friend
This Huntington's disease partnership could revolutionize treatments -- or fail out in trials. What does this new deal mean for Isis?The Next Potential Global Pandemic
Is it time to get worried again over China's avian flu? And what stocks hold the cure for investors portfolios?IBM and Genentech Introduce a New Era
Learning from the market's past to understand its present.Tackling Cancer: Melanoma's Biggest Current & Upcoming Players
Cancer research is big business, and it pays to know where research dollars are headed.RHHBY's Top Competitors
(0.57%)
(-0.10%)
(0.00%)
(0.21%)